Download pdf
Recent Advances in Gene Editing Cargo Delivery for Hematopoietic Stem and Progenitor Cells
- 1 South China University of Technology, Guangzhou, China, 511442
* Author to whom correspondence should be addressed.
Abstract
As the cornerstone of human hematopoiesis, hematopoietic stem and progenitor cells (HSPCs) sustain immune homeostasis by continuously generating blood cellular components. Their proliferative capacity and multilineage differentiation potential make them prime targets for gene therapy. The clinical application of HSPC genome editing relies on two key advancements: the development of highly specific and biocompatible genome-editing reagents and the establishment of efficient delivery systems ensuring targeted cellular uptake. Recent innovations in gene editing tools and cargo delivery methods, such as RNA- and protein-based editors, have enabled novel therapeutic strategies for hematological disorders. Current gene delivery platforms for HSPCs include electroporation, synthetic nanoscale carriers (e.g., polymeric and lipid nanoparticles), and engineered viral vectors such as integration-defective lentiviral vectors (IDLVs), adeno-associated viral vectors (AADVs), virus-like particles, and adenovirus vectors (AdVs). While ex vivo gene therapy remain predominant, it requires complex and costly patient conditioning regimens. in vivo approaches, primarily utilizing AdVs and LNPs, offer an alternative but lack sufficient targeting precision and transfection efficiency. By critically analyzing these advancements, this review aims to identify pathways for optimizing genome editing in HSPCs and enhancing therapeutic precision in hematological disorder management.
Keywords
Gene therapy, gene editing, gene delivery, hematopoietic stem and progenitor cells, blood disorders
[1]. Post Y, Clevers H (2019). Defining adult stem cell functionat its simplest: the ability to replace lost cells through mitosis. Cell Stem Cell 25:174-183.
[2]. Seita, J., & Weissman, I. L. (2010). Hematopoietic stem cell: self‐renewal versus differentiation. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2(6), 640-653.
[3]. Rekers, P. E., Coulter, M. P., & WARREN, S. L. (1950). Effect of transplantation of bone marrow into irradiated animals. Archives of Surgery, 60(4), 635-667.
[4]. Niederwieser, D., Baldomero, H., Bazuaye, N., Bupp, C., Chaudhri, N., Corbacioglu, S., et al. (2022). One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 107(5), 1045-1053.
[5]. Copelan, E. A. (2006). Hematopoietic stem-cell transplantation. New England Journal of Medicine, 354(17), 1813-1826.
[6]. Angelucci E, Matthes-Martin, S., Baronciani, D., et al. (2014). Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 99:811820.
[7]. Kim, S., Kim, D., Cho, S. et al. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome research, 24(6), 1012-1019.
[8]. Jinek, M., Chylinski, K., Fonfara, I., et al. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-821.
[9]. Cong, L., Ran, F. A., Cox, D., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819-823.
[10]. Jiang, T., Henderson, J. M., Coote, K., et al. (2020). Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. Nature communications, 11(1), 1979.
[11]. Liu, P., Liang, S. Q., Zheng, C., et al. (2021). Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat. Commun. 12, 2121.
[12]. Bak, R. O., Dever, D. P., Reinisch, A., et al. (2017). Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. Elife, 6, e27873.
[13]. Zeng, J., Wu, Y., Ren, C., et al. (2020). Therapeutic base editing of human hematopoietic stem cells. Nature Medicine, 26(4), 535-541.
[14]. Venkatesan, V., Christopher, A. C., Rhiel, M., et al. (2023). Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies. Molecular Therapy-Nucleic Acids, 32, 671-688.
[15]. Frangoul, H., Altshuler, D., Cappellini, M. D., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252-260.
[16]. Gul-Uludağ, H., Valencia-Serna, J., Kucharski, C., et al. (2014). Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells. Leukemia research, 38(11), 1299-1308.
[17]. El-Kharrag, R., Berckmueller, K. E., Madhu, R., et al. (2022). Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells. Molecular Therapy, 30(6), 2186-2198.
[18]. Li, C., & Samulski, R. J. (2020). Engineering adeno-associated virus vectors for gene therapy. Nature Reviews Genetics, 21(4), 255-272.
[19]. Büning, H., & Srivastava, A. (2019). Capsid modifications for targeting and improving the efficacy of AAV vectors. Molecular therapy Methods & clinical development, 12, 248-265.
[20]. Pavel-Dinu, M., Wiebking, V., Dejene, B. T., et al. (2019). Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nature communications, 10(1), 1634.
[21]. Rai, R., Romito, M., Rivers, E., et al. (2020). Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich Syndrome. Nature communications, 11(1), 4034.
[22]. Scharenberg, S. G., Poletto, E., Lucot, K. L., et al. (2020). Engineering monocyte/macrophage− specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing. Nature Communications, 11(1), 3327.
[23]. Wilkinson, A. C., Dever, D. P., Baik, R., et al. (2021). Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nature Communications, 12(1), 686.
[24]. Ling, C., Bhukhai, K., Yin, Z., et al. (2016). High-efficiency transduction of primary human hematopoietic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Scientific reports, 6(1), 35495.
[25]. Bak, R. O., & Porteus, M. H. (2017). CRISPR-mediated integration of large gene cassettes using AAV donor vectors. Cell reports, 20(3), 750-756.
[26]. Zhi, S., Chen, Y., Wu, G., et al. (2022). Dual-AAV delivering split prime editor system for in vivo genome editing. Molecular Therapy, 30(1), 283-294.
[27]. Mingozzi, F., & A High, K. (2011). Immune responses to AAV in clinical trials. Current gene therapy, 11(4), 321-330.
[28]. Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015). Viral vectors for gene therapy: translational and clinical outlook. Annual review of biomedical engineering, 17(1), 63-89.
[29]. Rothe, M., Modlich, U., & Schambach, A. (2013). Biosafety challenges for use of lentiviral vectors in gene therapy. Current gene therapy, 13(6), 453-468.
[30]. Liu, K. C., Lin, B. S., Gao, A. D., et al. (2014). Integrase-deficient lentivirus: opportunities and challenges for human gene therapy. Current gene therapy, 14(5), 352-364.
[31]. Wang, Y., Wang, Y., Chang, T., et al. (2017). Integration-defective lentiviral vector mediates efficient gene editing through homology-directed repair in human embryonic stem cells. Nucleic acids research, 45(5), e29.
[32]. Ferrari, S., Jacob, A., Cesana, D., et al. (2022). Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell, 29(10), 1428-1444.
[33]. Abdul-Razak, H. H., Rocca, C. J., Howe, S. J., et al. (2018). Molecular evidence of genome editing in a mouse model of immunodeficiency. Scientific reports, 8(1), 8214.
[34]. Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., ... & Liu, D. R. (2022). Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell, 185(2), 250-265.
[35]. Cai, X., Dou, R., Guo, C., et al. (2023). Cationic polymers as transfection reagents for nucleic acid delivery. Pharmaceutics, 15(5), 1502.
[36]. Rai, R., Alwani, S., & Badea, I. (2019). Polymeric nanoparticles in gene therapy: New avenues of design and optimization for delivery applications. Polymers, 11(4), 745.
[37]. Canine, B. F., & Hatefi, A. (2010). Development of recombinant cationic polymers for gene therapy research. Advanced drug delivery reviews, 62(15), 1524-1529.
[38]. Weiss, A. M., Lopez, M. A., Rawe, B. W., et al. (2023). Understanding How Cationic Polymers’ Properties Inform Toxic or Immunogenic Responses via Parametric Analysis. Macromolecules, 56(18), 7286-7299.
[39]. Kulkarni, J. A., Witzigmann, D., Thomson, S. B., et al. (2021). The current landscape of nucleic acid therapeutics. Nature nanotechnology, 16(6), 630-643.
[40]. Cheng, Q., Wei, T., Farbiak, L., et al. (2020). Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nature nanotechnology, 15(4), 313-320.
[41]. Shepherd, S. J., Han, X., Mukalel, A. J., et al. (2023). Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proceedings of the National Academy of Sciences, 120(33), e2303567120.
[42]. El-Kharrag, R., Berckmueller, K. E., Madhu, R., et al. (2022). Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells. Molecular Therapy, 30(6), 2186-2198.
[43]. Breda, L., Papp, T. E., Triebwasser, M. P., et al. (2023). in vivo hematopoietic stem cell modification by mRNA delivery. Science, 381(6656), 436-443.
[44]. Shi, D., Toyonaga, S., & Anderson, D. G. (2023). in vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles. Nano Letters, 23(7), 2938-2944.
Cite this article
Tang,Y. (2025). Recent Advances in Gene Editing Cargo Delivery for Hematopoietic Stem and Progenitor Cells. Theoretical and Natural Science,103,35-41.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 5th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).